Search

Here, we present the initial results of a phase 1 dose escalation study of the combination SEL and RUX in treatment-naive MF. One patient required dose interruption due to dizziness and later discontinued treatment due to new onset of atrial fibrillation and pulmonary hypertension (unrelated to SEL and RUX) after 5 months of therapy. Keywords: Clinical Research; Clinical Trials and Studies; Drugs and Therapies; Health and Medicine; Hematology; Hemic and Immune Systems; Kinase Inhibitors; Lymphoid Tissue; Myelofibrosis; Pharmaceuticals; Protein Kinase Inhibitors; Ruxolitinib Therapy; Spleen EN Clinical Research Clinical Trials and Studies Drugs and Therapies Health and Medicine Hematology Hemic and Immune Systems Kinase Inhibitors Lymphoid Tissue Myelofibrosis Pharmaceuticals Protein Kinase Inhibitors Ruxolitinib Therapy Spleen 766 766 1 06/26/23 20230626 NES 230626 2023 JUN 26 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Week -- Investigators publish new report on myelofibrosis. [Extracted from the article]

2022 AUG 27 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Researchers detail new data in myelodysplastic syndromes. According to news originating from [...]